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Abstract: Black cumin (Nigella sativa) seed extract has been shown to improve dermatological
conditions, yet its beneficial effects for skin are not fully elucidated. Herein, Thymocid® , a chemically
standardized black cumin seed extract, was investigated for its cosmeceutical potential including
anti-aging properties associated with modulation of glycation, collagen cross-linking, and collagenase
and elastase activities, as well as antimelanogenic effect in murine melanoma B16F10 cells. Thymocid®
(50, 100, and 300 µg/mL) inhibited the formation of advanced glycation end-products (by 16.7–70.7%),
collagen cross-linking (by 45.1–93.3%), collagenase activity (by 10.4–92.4%), and elastases activities
(type I and III by 25.3–75.4% and 36.0–91.1%, respectively). In addition, Thymocid® (2.5–20 µg/mL)
decreased melanin content in B16F10 cells by 42.5–61.6% and reduced cellular tyrosinase activity by
20.9% (at 20 µg/mL). Furthermore, Thymocid® (20 µg/mL for 72 h) markedly suppressed the mRNA
expression levels of melanogenesis-related genes including microphthalmia-associated transcription
factor (MITF), tyrosinase-related protein 1 (TYRP1), and TYRP2 to 78.9%, 0.3%, and 0.2%, respectively.
Thymocid® (10 µg/mL) also suppressed the protein expression levels of MITF (by 15.2%) and TYRP1
(by 97.7%). Findings from this study support the anti-aging and antimelanogenic potential of
Thymocid® as a bioactive cosmeceutical ingredient for skin care products.
Keywords: black cumin; Nigella sativa; Thymocid® ; skin aging; glycation; collagen; collagenase;
elastase; melanogenesis; cosmeceutical

1. Introduction
Nigella sativa Linn. (family Ranunculaceae), commonly known as black seed, black cumin, or
cumin noir, originated in regions of Eastern Europe, the Middle East, northern Africa, the Indian
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www.mdpi.com/journal/nutrients

Nutrients 2020, 12, 2146

2 of 16

subcontinent, and the west and middle of Asia [1]. In these regions, it has a long history of use for
culinary purpose as a spice, natural seasoning, or flavoring, as well as for medicinal purposes in
traditional folk medicine systems to treat a variety of ailments [2]. Black cumin seeds are recognized for
their great nutritional value as a source of nutrients including iron, copper, zinc, phosphorus, calcium,
thiamin, niacin, pyridoxine, and folic acid [3]. In addition, black cumin seeds are a good source of
plant-based proteins as they have been reported to have a high index of net protein utilization, protein
efficiency ratio, and net dietary protein energy percent [3]. Moreover, phytochemical investigations of
black cumin seeds revealed that thymoquinone (TQ) and its derivatives including thymohydroquinone,
dithymoquinone, thymol, and carvacrol are the major chemicals in black cumin seed oil [4]. In
addition, other phytochemicals, such as alkaloids including nigellicine, nigellimine, nigellidine,
17-O-(β-d-glucopyranosyl)-4-O-methylnigellidine, 4-O-methylnigellidine, nigelanoid, nigeglanine, and
4-O-methylnigeglanine have been identified as minor constituents of black cumin seed oil [4–6]. Apart
from their nutritional values, black cumin seed extracts (BCSEs) have been reported to display diverse
biological and pharmacological activities including antioxidant, anti-inflammatory, anticarcinogenic
and antimutagenic, antidiabetic, antimicrobial, and immunological effects [7–10]. Moreover, pre-clinical
and clinical studies have reported efficacious activities of BCSEs on dermatological conditions. Several
in vitro studies demonstrated that protective effects of a BCSE on cutaneous disorders could be
attributed to its antimicrobial effects including antibacterial, antiviral, antifungal, and antiparasitic
activity [11]. BCSE’s antimicrobial effects have also been studied in a clinical trial, where a treatment
with 10% oil lotion of BCSE for 2 months exerted an anti-acne effect via reduction in the mean
lesion count of papules and pustules [12]. However, only limited number of studies have reported
BCSEs’ cosmeceutical applications, such as its modulatory effects on the production of melanin in the
melanophores from wall lizard (Podarcis muralis), which was attributed to the stimulation of cholinergic
receptors [13]. However, to date, the cosmeceutical effects of BCSE as an antiwrinkle/-aging agent,
have not yet been reported.
Skin wrinkling is a natural and observable index of the process of aging. It can be exacerbated
by a combination of external oxidative stress (e.g., ultraviolet light radiation and pollutants) and
endogenous factors (e.g., protein glycation and degradation). Skin wrinkles are formed when the
physiological structure of skin tissue is impaired. Skin structure is collectively maintained by a group
of connective and supportive proteins including collagen, elastin, claudin, laminin, nidogen, occludin,
zonula occludens, and junctional adhesion molecule [14–18]. Amongst these proteins, collagen and
elastin are major supportive molecules for the structure of skin tissue, and their structural damage and
degradation are directly associated with the formation of skin wrinkles [16]. Collagen is a long-lasting
protein with a half-life of over a decade and is subject to chronic internal stress such as glycation. The
formation of advanced glycation end-products (AGEs) leads to the alteration of protein structure and
the generation of free radicals, which further results in the impairment of the protein’s physiological
functions including its ability of maintaining the structure of skin tissue. Protein degradation is
another crucial contributing factor to the formation of skin wrinkles [14]. Elastin, an elastic protein
that maintains skin structure following stretching or contraction, can be degraded by a protease
enzyme known as elastase [19]. Therefore, antiglycation agents and inhibitors of collagenase and
elastase from dietary natural products have attracted immense research interest for the management of
skin aging [20]. However, the protective effects of BCSEs against collagen and elastin degradation
remain unclear.
Over the past decade, our laboratory has conducted phytochemical and biological investigations
of dietary natural products including extracts of medicinal plants and functional foods. During
the course of our studies, several botanical extracts exhibited promising anti-aging and beneficial
effects for skin [21–23]. Among these herbal extracts, a BCSE was investigated for its phytochemical
constituents and biological effects. This led to the identification of TQ (as the major phytochemical of
this BCSE) and other bioactive compounds such as indazole-type alkaloids with antihyperglycemic
effects [6]. A proprietary BCSE, namely, Thymocid® , is commercially produced by a cold compressed
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method without the use of extraction solvents. It contains omega-6 fatty acids such as linoleic acid
and is chemically standardized to TQ content. As part of our group’s continuing research efforts to
study the beneficial effects to skin of bioactive dietary ingredients, the current study was designed to
evaluate the cosmeceutical properties of Thymocid® with in vitro enzymatic and cell-based assays for
(1) effects on glycation of bovine serum albumin and collagen cross-linking; (2) anticollagenase and
anti-elastase activities; (3) effects on melanogenesis in murine melanoma B16F10 cells; and, (4) effects
on the expressions of melanogenesis-related genes and proteins in B16F10 cells.
2. Materials and Methods
2.1. Chemicals
Thymoquinone (TQ), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfenyl)2-H-tetrazolium salt (MTS), methanol (analytical grade), trifluoroacetic acid, Tris-HCl
buffer (pH 10), phosphate buffer saline (PBS, pH 7.4), kojic acid, aminoguanidine
(AG), epigallocatechin gallate (EGCG), L-tyrosine, L-3,4-dihydroxyphenylalanine (L-DOPA),
N-succinyl-Ala-Ala-ala-p-nitroanilide (AAAPVN), mushroom tyrosinase, elastase enzymes (type I
and III) from porcine pancreas, bovine serum albumin (BSA), methylglyoxal (MGO),
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
reagent, Triton X-100 agent, and sodium azide were purchased from Sigma-Aldrich Co. (St. Louis, MO,
USA). Bovine type I collagen was obtained from Advanced BioMatrix Inc. (PureCol® , Catalog #5005;
Carlsbad, CA, USA). A commercially available black cumin seed extract (Thymocid® ) was kindly
provided by Verdure Sciences (Noblesville, IN, USA).
2.2. Quantification of Thymoquinone (TQ) in Thymocid®
The level of TQ in Thymocid® was quantified by using the high-performance liquid
chromatography (HPLC) method with an Hitachi HPLC instrument (Hitachi Instruments, Inc.,
San Jose, CA, USA), an Alltima C18 column (250 × 4.6 mm i.d., 5 µm), and a solvent system consisting of
0.1% trifluoroacetic acid in water (A) and methanol (B). A linear gradient eluting method was used as
follows: 0–20 min, 50–100% B; 20–21 min, 100–50% B; 20–28 min, 50 % B with a total run time of 28 min,
a flow rate of 0.75 mL/min, and an injection volume of 10 µL. Thymocid® was dissolved in dimethyl
sulfoxide (DMSO) at various concentrations (0.1–4 mg/mL) and monitored at a range of wavelengths
from 200 to 400 nm with a photodiode array detector (see Supplementary Materials Figure S1). A
standard curve of TQ at various concentrations (1–200 µg/mL) monitored at the wavelength of 254 nm,
which is the characteristic wavelength for TQ, was constructed for its quantification in Thymocid®
(see Supplementary Materials Figure S2).
2.3. Bovine Serum Albumin (BSA)–Fructose Glycation Assay
The antiglycation assay was performed according to previously reported methods using a
BSA–fructose model [24]. Briefly, a BSA–fructose reaction mixture containing BSA (10 mg/mL) and
D-fructose (100 mM) was prepared in phosphate buffer saline (PBS; 0.2 M, pH 7.2). Next, different
concentrations of Thymocid® (50, 100, and 300 µg/mL) were added to the BSA—fructose mixture and
incubated at 37 ◦ C on a shaking rack for a duration of 14 days. Aminoguanidine (AG) was used as a
positive control. The formation of AGEs was monitored by the measurement of intrinsic fluorescence
at excitation and emission wavelengths of 340 and 435 nm, respectively, using a plate reader.
2.4. Collagen Cross-Linking Assay
A reaction mixture consisting of bovine type I collagen (1.5 mg/mL), Thymocid® (at 50, 100,
and 300 µg/mL), methylglyoxal (MGO; 5 mM), and sodium azide (10 mM) in PBS was incubated at
37 ◦ C for 30 days. The reaction mixture of each sample (200 µL) was then transferred to a 96-well
black fluorescence reading plate. The level of cross-linked collagen was monitored by measuring

Nutrients 2020, 12, 2146

4 of 16

the fluorescent intensity of each well with excitation and emission wavelengths at 340 and 435 nm,
respectively, using a plate reader.
2.5. Collagenase Inhibition Assay
A collagenase inhibition assay was conducted using a collagenase activity assay kit (Abcam
Inc., Cambridge, MA, USA) following the manufacturer’s instructions. Briefly, assay buffer (180 µL)
and a mixture of test sample at various concentrations or a positive control, 1,10-phenanthroline
(10 µL), and collagenase solution (10 µL) were incubated in a 96-well plate at 37 ◦ C for 15 min. The
substrate N-(3-[2-furyl]-acryloyl)-Leu-Gly-Pro-Ala (FALGPA) solution (100 µL) was then added to
each well. The absorbance of each well was recorded at a wavelength of 345 nm with a kinetic
mode for 30 min using a plate reader. The activity of collagenase was calculated as follow:
collagenase activity = (∆ODc/∆T) × 0.2/(0.53 × V), where ∆ODc = difference of optical density
(OD) reading from sample at different time points, 0.2 = reaction volume (mL), 0.53 = millimolar
extinction coefficient of FALGPA, V = sample volume added into the reaction well (mL). The inhibition
rate was calculated as inhibition% = 100 × (ActivityEnzyme − ActivitySample )/ActivityEnzyme %.
2.6. Elastase Inhibition Assay
An elastase inhibition assay was conducted using previously reported methods with minor
modifications [25]. Briefly, a mixture of test samples (10 µL), elastase solution (20 µL; 0.5 U/mL), and
Tris-HCl buffer (140 µL; 2 mM; pH 8.0) were incubated in a 96-well plate at room temperature for
15 min. Then, substrate AAAPVN solution (50 µL; 1 mg/mL) in Tris-HCL buffer was added to each well,
and the reaction mixtures were allowed to incubate at room temperature for 1 min. The absorbance of
each well was recorded at a wavelength of 410 nm using a plate reader.
2.7. Tyrosinase Inhibition Assay
A tyrosinase inhibition assay was conducted as per previously reported methods with slight
modifications [26]. In brief, a mixture of test samples (40 µL) and mushroom tyrosinase solution
(100 U/mL) in PBS (0.1 M; 120 µL) was incubated in wells of a 96-well plate at room temperature for
15 min. Following incubation, L-tyrosine solution (2.5 mM; 40 µL) or L-DOPA solution (2.5 mM; 40 µL)
in PBS was added to each well, and the reaction mixtures were incubated at 37 °C for 30 min. The
absorbance of each well was recorded at a wavelength of 490 nm using a plate reader.
2.8. Cell Culture
Murine melanoma B16F10 cells obtained from American Type Culture Collection (ATCC, Rockville,
MD, USA) were cultured as recommended by ATCC. Briefly, B16F10 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM; Life Technologies, Gaithersburg, MD, USA) supplemented with 10%
fetal bovine serum (Life Technologies) and 1% antibiotic solution (Sigma-Aldrich Co., St. Louis, MO,
USA). Cells were maintained at 37 ◦ C in the presence of 5% CO2 and constant humidified atmosphere.
Test samples were dissolved in DMSO as stock solution and then diluted with cell culture medium to
the desired concentrations (DMSO < 0.1%).
2.9. Cell Viability Assay
The viability of B16F10 cells was determined by the MTS assay as described previously with minor
modifications [27]. Briefly, cells were seeded in 96-well plates at a density of 5 × 103 cells per well and
allowed to attach overnight. Next, the culture medium was replaced with fresh medium supplemented
with various concentrations of Thymocid® (2.5, 5, 10, 20, and 40 µg/mL) for 72 h. After the incubation,
freshly prepared MTS reagent (20 µL) was added to each well and incubated at 37 ◦ C for 30 min, and
optical density of each well was measured at a wavelength of 490 nm using a plate reader.
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2.10. Melanogenesis Assay
The antimelanogenic effect of Thymocid® was evaluated by the measurement of melanin content
in B16F10 cells following previously reported method with modifications [27]. Briefly, cells were
seeded in 96-well plates at a density of 5 × 103 cells per well and allowed to attach for 24 h. Cells were
then treated with Thymocid® at concentrations of 2.5, 5, 10, and 20 µg/mL for 72 h. Then cells were
lysed by adding sodium hydroxide solution (0.1 M; 1 mL), and lysed cells were centrifuged (3000× g for
5 min). The supernatant was decanted, and the cell pellet was exposed to sodium hydroxide (200 µL),
followed by placing in a water bath at 80 ◦ C for 1 h. Samples were then briefly mixed by vortex, and
melanin content was transferred to a 96-well plate. The absorbance of each well was measured at a
wavelength of 405 nm using a plate reader.
2.11. Cellular Tyrosinase Activity Assay
The cell-based tyrosinase assay was performed using a previously reported method with
modifications [28]. Briefly, B16F10 cells were seeded at 4 × 104 cells per well in a 24-well plate
and allowed to grow for 24 h prior to being treated with Thymocid® (2.5, 5, 10, and 20 µg/mL) for
72 h. Next, cells were harvested and washed twice with ice-cold PBS followed by centrifugation at
12,000× g for 10 min, and cells pellets were re-suspended in PBS containing Triton X-100 (1%). The cells
were lysed by a freeze-and-thaw cycle to release tyrosinase from the melanosome membrane. Cellular
tyrosinase was collected by centrifugation at 10,000× g at 4 ◦ C for 30 min. A reaction mixture consisting
of cellular tyrosinase (20 µg in 200 µL of PBS) and L-DOPA solution (1.25 mM) was incubated at
37 ◦ C for 30 min. The formation of dopachrome was quantified by measuring the optical density at a
wavelength of 495 nm using a plate reader.
2.12. Real-Time Polymerase Chain Reaction (RT-PCR)
The mRNA expression level of melanin-synthesis-related genes including microphthalmiaassociated transcription factor (MITF), tyrosinase (TYR), tyrosinase-related protein-1 (TYRP1), and
tyrosinase-related protein-2 (TYRP2) were measured by a real-time polymerase chain reaction (RT-PCR)
assay with a previously reported method [27]. Briefly, B16F10 cells were seeded in 6-well plates at a
density of 1 × 105 cells per well and allowed to grow for 24 h. Then cells were treated with Thymocid®
(2.5 or 10 µg/mL) for 24, 48, or 72 h. Total RNA was isolated from cells using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions. The extracted genes were quantified
by using a SYBR Green kit (Thermo Fisher Scientific, Grand Island, NY, USA) and compared to levels
of b2m rRNA as a reference housekeeping gene.
2.13. Preparation of Cellular Protein Lysates and Western Blot Assay
B16F10 cells were seeded in 6-well plates at a density of 1.0 × 105 cells per well and allowed to
grow for 24 h and were then treated with Thymocid® (2.5 and 10 µg/mL) and cultured for 72 h. After
washing with PBS, B16F10 cells were harvested, whole-cell lysates were prepared and quantified, and
the protein expressions of MITF, TYR, TYRP1, and TYRP2 were quantified by Western blot assay, as
described previously [27]. Antibodies including anti-MITF (ab3201), anti-TYRP1 (ab178676), anti-TYRP2
(ab103463), and anti-β-Actin antibody (ab8227) were obtained from Abcam, Cambridge, MA, USA.
The western blot (WB) bands were detected on X-ray films using an enhanced chemiluminescence
(ECL) detection kit (GE Healthcare, Piscataway, NJ, USA) according to the manufacturer’s protocol.
2.14. Statistical Analyses
Data are presented as mean ± standard deviation (S.D.) of at least three replicated experiments.
Two-tailed unpaired Student’s t test or ANOVA with Tukey post-test was used for statistical analysis
of the data using the GraphPad Prism software 6.0 or Office Excel 2010 software. Significance for all
tests was defined as p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****).
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replicates. Significance was defined as ** p < 0.01 and *** p < 0.001 when compared to the control
7 of 16
group.
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Figure 3. The optical density at a wavelength of 345 nm (OD345) values of collagenase enzyme treated
with Thymocid® ®or a positive control phen (1,10-phenanthroine), over 30 min in a kinetic mode (A).
with Thymocid or a positive control phen (1,10-phenanthroine), over 30 min in a kinetic mode (A).
The inhibitory effect of Thymocid® ®(62.5–1000 µg/mL) and phen (10 mM) on collagenase activity was
The inhibitory effect of Thymocid (62.5–1000 µ g/mL) and phen (10 mM) on collagenase activity was
measured by a colorimetric assay (B). The inhibition rates are expressed as mean ± S.D. from three
measured by a colorimetric assay (B). The inhibition rates are expressed as mean ± S.D. from three
replicated experiments. Significance was defined as ** p < 0.001 and *** p < 0.0001 when compared to
replicated experiments. Significance was defined as ** p < 0.001 and *** p < 0.0001 when compared to
the control group.
the control group.

3.3. Thymocid® Inhibits Elastase Activity
3.3. Thymocid® Inhibits Elastase Activity
Thymocid® was further evaluated for its antiwrinkle property by measuring its inhibitory effects
® was further evaluated for its antiwrinkle
property by measuring
inhibitory
effects
on the Thymocid
activity of elastases
(type I and III). Thymocid® (at concentrations
of 62.5–1000itsµg/mL)
inhibited
®
on theactivities
activity inofa concentration-dependent
elastases (type I and III).
Thymocid
(at concentrations
of 62.5–1000
µ g/mL)
elastase
manner
as it reduced
the activity of type
I and III elastase
inhibited
elastase
activities
in
a
concentration-dependent
manner
as
it
reduced
the
activity
of
type I
by 25.3–75.4% and 36.0–91.1%, respectively (Table 1). Epigallocatechin gallate (EGCG; 92 µg/mL),
and
III
elastase
by
25.3–75.4%
and
36.0–91.1%,
respectively
(Table
1).
Epigallocatechin
gallate
(EGCG;
used as a positive control, provided an inhibition rate of 73.0% and 75.2% on type I and III elastase,
92 µ g/mL), used
as a be
positive
anphytochemical
inhibition ratein
ofThymocid
73.0% and®75.2%
on type Ithe
and
respectively.
It should
notedcontrol,
that TQ,provided
the major
, also reduced
® , also
III
elastase,
respectively.
It
should
be
noted
that
TQ,
the
major
phytochemical
in
Thymocid
activities of collagenase and elastases (type I and III) by 18.0–30.0%, 16.1–30.2%, and 12.9–45.3%, at
reduced the activities
of collagenase
and1000
elastases
(type
I and III) (see
by 18.0–30.0%,
16.1–30.2%,
and
concentrations
of 62.5, 125,
250, 500, and
µg/mL,
respectively
Supplementary
Materials
12.9–45.3%,
at
concentrations
of
62.5,
125,
250,
500,
and
1000
µ
g/mL,
respectively
(see
Supplementary
Tables S1 and S2).
Materials Tables S1 and S2).

Sample
Sample
®
Thymocid
Thymocid®

a

EGCG bb
EGCG

Table 1. Inhibitory activity of Thymocid® on elastase enzyme.
Table 1. Inhibitory activity of Thymocid® on elastase enzyme.
Inhibition Rate (%) a
Concentration (µg/mL)
Inhibition Rate (%) a
Concentration (µg/mL) Type-I
Type-III
Type-I
Type-III
1000 1000
75.4 ± 4.5
75.4 ± 4.5 91.1 ± 1.2
91.1 ±1.2
500 500
69.2 ± 1.3
69.2 ± 1.3 88.6 ± 2.3
88.6 ± 2.3
250 250
56.2 ± 3.2
56.2 ± 3.2 78.4 ± 3.2
78.4 ± 3.2
125
35.4 ± 6.9
61.3 ± 2.1
125
35.4 ± 6.9
61.3 ± 2.1
62.5
25.3 ± 5.9
36.0 ± 2.7
62.5
25.3 ± 5.9
36.0 ± 2.7
92
73.0 ± 1.8
75.2 ± 4.0
92
73.0 ± 1.8
75.2 ± 4.0

Values are expressed as mean ± S.D. from three replicated experiments.

b

Epigallocatechin gallate; positive control.
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3.4. Thymocid® Increases Tyrosinase Activity
We further evaluated the effects of Thymocid® in melanin-biosynthesis-related bioassays. First,
Thymocid® was evaluated for its modulatory effect on tyrosinase activity using two enzyme substrates
including L-tyrosine and L-DOPA. As shown in Table 2, when tested with the different substrates,
Thymocid® (62.5–1000 µg/mL) dose-dependently increased the activity of tyrosinase to 153.3–228.7%
for L-tyrosine as substrate, and 113.7–146.3% for L-DOPA as substrate, respectively (Table 2). Kojic acid
(at 10 µg/mL), a known tyrosinase inhibitor, was included as a positive control and it reduced tyrosinase
activity to 49.5% and 66.1%, respectively. In addition, TQ (at 62.5, 125, 250, 500, and 1000 µg/mL) also
increased the activity of tyrosinase to 120.7–110.8% and 100.8–117.7%, respectively, when assayed with
substrates L-tyrosine and L-DOPA (see Supplementary Materials Table S3).
Table 2. Modulatory effect of Thymocid® on the activity of tyrosinase enzyme. Thymocid® was
evaluated with mushroom tyrosinase with two substrates including L-tyrosine and L-DOPA.
Sample
Thymocid®

Kojic acid b
a

Concentration (µg/mL)
1000
500
250
125
62.5
10

Enzyme Activity (%) a
L-Tyrosine

L-DOPA

228.7 ± 9.6
192.0 ± 12.3
170.0 ± 6.8
162.5 ± 7.3
153.3 ± 6.6
49.5 ± 3.0

146.3 ± 18.6
133.1 ± 6.1
133.9 ± 15.4
116.1 ± 6.7
113.7 ± 3.0
66.2 ± 13.2

Values are expressed as mean ± S.D. from three replicated experiments.

b

Positive control.

3.5. Thymocid® Reduces the Melanin Content in B16F10 Melanoma Cells
To further evaluate whether Thymocid® can modulate the production of melanin, cell-based
assays were conducted in murine melanoma B16F10 cells. The cytotoxicity of Thymocid® (2.5, 5,
10, 20, and 40 µg/mL) on B16F10 cells was evaluated by measuring cell viability using the MTS
assay. Thymocid® was nontoxic to B16F10 cells at concentrations ranging from 2.5 to 20 µg/mL,
as it maintained the viability of B16F10 cells greater than 95.7% (Figure 4A), and these nontoxic
concentrations were selected for further bioassays. Next, the antimelanogenic effect of Thymocid® in
B16F10 cells was evaluated. We observed that Thymocid® (2.5, 5, 10, and 20 µg/mL) suppressed the
production of melanin (Figure 4B) to 57.5%, 56.1%, 52.9%, and 38.4%, respectively, as compared to the
control group without treatment of Thymocid® (Figure 4C). Furthermore, we assessed the effect of
Thymocid® on cellular tyrosinase activity in B16F10 cells. Compared to the control group, Thymocid®
reduced cellular tyrosinase activity by 20.9% at the highest tested concentration (20 µg/mL) (Figure 4D).
3.6. Thymocid® Suppresses the mRNA and Protein Expression Levels of Melanogenesis-Related Markers in
B16F10 Cells
To further investigate the mechanism of Thymocid® ’s suppression of melanogenesis (i.e., melanin
production) in B16F10 cells, its effects on the expression of melanogenesis-related genes including
MITF, TYR, TYRP1, and TYRP2 were evaluated. As shown in Figure 5A, treatment of B16F10 cells
with Thymocid® (at 20 µg/mL) for 24, 48, or 72 h, suppressed the mRNA expression of MITF, TYR,
TYRP1, and TYRP2 in a time-dependent manner. At 48 and 72 h, treatment with Thymocid® had
a suppressive effect on the expression of MITF, TYR, TYRP1, and TYRP2 as it reduced their mRNA
expression to 42.0%, 76.5%, 62.2%, and 61.2%, and 3.3%, 83.6%, 0.3%, and 0.2%, respectively, whereas
it only reduced expression of MITF to 78.9% within 24 h (Figure 5A). Moreover, we observed that
treatment with Thymocid® , at 2.5 and 10 µg/mL, resulted in a concentration-dependent modulation of
mRNA expression of MITF, TYR, TYRP1, and TYRP2 to 80.1%, 98.6%, 93.4%, and 93.7%, and 73.0%,
104.9%, 76.6%, and 86.6%, respectively (Figure 5B).
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B16F10 cells (A), melanin content (B), and its quantification (C) in B16F10 cells cultured with Thymocid®
B16F10 cells (A), melanin content (B), and its quantification (C) in ®B16F10 cells cultured with
for 72 h, and cellular tyrosinase activity in B16F10 cells treated with Thymocid for 72 h (D). Significance
Thymocid® for 72 h, and cellular tyrosinase activity in B16F10 cells treated with Thymocid® for 72 h
was defined as ** p < 0.01 and *** p < 0.001 when compared to the control group and values are
(D).
Significance
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as ** three
p < 0.01
and *** p replicates.
< 0.001 when compared to the control group and
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± S.D. from
experiment
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3.6. Thymocid® Suppresses the mRNA and Protein Expression Levels of Melanogenesis-Related Markers in
B16F10 Cells
To further investigate the mechanism of Thymocid® ’s suppression of melanogenesis (i.e.,
melanin production) in B16F10 cells, its effects on the expression of melanogenesis-related genes
including MITF, TYR, TYRP1, and TYRP2 were evaluated. As shown in Figure 5A, treatment of
B16F10 cells with Thymocid® (at 20 µ g/mL) for 24, 48, or 72 h, suppressed the mRNA expression of
MITF, TYR, TYRP1, and TYRP2 in a time-dependent manner. At 48 and 72 h, treatment with
Thymocid® had a suppressive effect on the expression of MITF, TYR, TYRP1, and TYRP2 as it reduced
their mRNA expression to 42.0%, 76.5%, 62.2%, and 61.2%, and 3.3%, 83.6%, 0.3%, and 0.2%,
respectively, whereas it only reduced expression of MITF to 78.9% within 24 h (Figure 5A). Moreover,
we observed that treatment with Thymocid® , at 2.5 and 10 µ g/mL, resulted in a concentrationdependent modulation of mRNA expression of MITF, TYR, TYRP1, and TYRP2 to 80.1%, 98.6%,
93.4%, and 93.7%, and 73.0%, 104.9%, 76.6%, and 86.6%, respectively (Figure 5B).
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Next, we evaluated the effect of Thymocid® on the expression levels of proteins related to
melanogenesis in B16F10 cells by Western blotting
assay. The densitometric data showed that
Next, we evaluated the effect of Thymocid® on the expression levels of proteins related to
treatment with Thymocid® reduced the expression of TYRP1 and TYRP2 in B16F10 cells (Figure 6A).
melanogenesis in B16F10 cells by Western blotting assay. The densitometric
data showed that
Quantitative analysis of data from Western blotting assay revealed that Thymocid® (2.5 and 10 µg/mL)
treatment with Thymocid® reduced the expression of TYRP1 and TYRP2 in B16F10 cells (Figure 6A).
reduced suppressed the protein expression levels of TYRP1 (by 69.1–97.7%) and TYRP2 (by 9.4–9.3%),
Quantitative analysis of data from Western blotting assay revealed that Thymocid® (2.5 and 10
respectively (Figure 6B), whilst the expression of MITF was only slightly decreased by the treatment
µ g/mL) reduced
suppressed the protein expression levels of TYRP1 (by 69.1–97.7%) and TYRP2 (by
with Thymocid® by 18.8–15.2% at 2.5 and 10 µg/mL, respectively) (Figure 6B).
9.4–9.3%), respectively (Figure 6B), whilst the expression of MITF was only slightly decreased by the
treatment with Thymocid® by 18.8–15.2% at 2.5 and 10 µ g/mL, respectively) (Figure 6B).
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Equal protein loading was confirmed by using protein β-actin as an internal household protein. The
including MITF, TYRP1, and TYRP2 were determined by Western blotting assay (densitometric data;
protein expression in B16F10 cells treated with Thymocid® (2.5 and 10 µg/mL) for 72 h were compared
A). Equal protein loading was confirmed by using protein β-actin as an internal household protein.
to the control group (B). Values are presented as the means ± S.D. from three experimental replicates.
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Thymoquinone (TQ), a major bioactive compound in BCSE [29], was used to standardize
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present in
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including anti-elastase
and
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conducted in this study (Supplementary Materials Tables
S1–S3); however, TQ at similar concentrations was less active than Thymocid® , suggesting that other
phytochemicals present in Thymocid® also contributed to its overall biological effects. In addition,
although only one major peak appeared in the HPLC chromatogram of Thymocid® monitored at the
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although only one major peak appeared in the HPLC chromatogram of Thymocid® monitored at the
wavelength of 254 nm (retention time at 16.5 min; Figure 1), it is possible that other phytochemicals,
including non-aromatic molecules, such as aliphatic compounds, may also be present in Thymocid®
without being detectable by HPLC analysis. Future studies to identify these aliphatic compounds using
proper analytical tools (e.g., gas chromatography–mass spectrometry) and evaluate their biological
activities are warranted. Moreover, the presence of other TQ derivatives including thymol, carvacrol,
thymohydroquinone, and dithymoquinone, as well as alkaloids including nigellicine, nigellimine,
nigellidine, and nigelanoid are also reported in published studies on the chemical composition of
BCSEs [4,6]. Although compounds including carvacrol and thymol were not identified and quantified in
Thymocid® in the current study, it has been reported that carvacrol and thymol exhibited skin-protective
effects including inhibitory effects on collagenase and elastase [31]. Therefore, it is possible that several
phytochemicals including aliphatic compounds and alkaloids in Thymocid® may also exert biological
effects that contribute to the overall skin beneficial effects of BCSE. Therefore, a “whole-food” approach
was used to evaluate the biological effects of Thymocid® , rather than testing its individual compounds.
Thymocid® showed anti-aging effects by maintaining protein structure against glycation (Figure 2).
The inhibitory effect of Thymocid® on the formation of AGEs in a BSA–fructose model (Figure 2A) was
in agreement with a published study showing that TQ reduced the formation of AGEs in a model with
human serum albumin and glucose [32]. In addition, a BCSE has been reported to show preventive
effects against glycation-induced DNA damage [33]. Furthermore, Thymocid® protected the structure
of bovine type I collagen from glycation-induced cross-linking (Figure 2B). Given that the formation of
AGEs is an oxidative process, it is possible that the antiglycation effect of Thymocid® may attribute to
its antioxidant effects [34]. The protective effects of Thymocid® on the structure of skin’s connective
proteins were supported by its anti-collagenase (Figure 3) and anti-elastase activities (Table 1). This is
in agreement with a published study showing that a BCSE was able to inhibit the activity of human
neutrophil elastase [35]. However, due to the structural and functional difference between porcine
pancreatic elastase and human neutrophil elastase [36], further studies on Thymocid® ’s effects on
elastase in human skin fibroblast cells are warranted to support its antiwrinkle effects.
Melanin, the end-product of melanogenesis, is produced in melanocytes within melanosomes.
It is a critical factor for the color of various organs and tissues including eyes, hair, and skin [37–39].
Melanin’s main role is related to skin protection against ultraviolet rays; however, excessive production
and accumulation of melanin lead to cutaneous hyperpigmentation disorders, including freckles, skin
discoloration, and pigmented age spots [38,40]. Over the years, this can lead to the enhancement of the
degradation of cutaneous extracellular matrix proteins as observed in biological processes including
skin aging, discoloration, and solar elastosis [41]. The process of melanogenesis is catalyzed by three
major melanocyte-specific enzymes, namely, TYR, TYRP1, and TYRP2 (also known as dopachrome
tautomerase) [40], with TYR being the rate-limiting enzyme for melanin biosynthesis [42–44]. These
enzymes are appropriate targets for the improvement of skin conditions including skin tone, aging,
whitening, or discoloration with plant-based nutrients [42,45]. Thymocid® promoted the activity of
tyrosinase, which corroborates a previously reported study showing that BCSE was able to increase
melanin production in melanophores isolated from wall lizard (Podarcis muralis) [29]. However, further
evaluations on the melanin content in murine melanoma B16F10 cells indicated that Thymocid® ,
at nontoxic concentrations, suppressed the production of melanin (Figure 4B,C) while it decreased
cellular tyrosinase activity (Figure 4D). This is similar to a previously reported study, in which a BCSE
was able to reduce melanin production in B16F10 cells stimulated with alpha-melanocyte-stimulating
hormone [46]. The BCSE’s antimelanogenic effect (observed in this study and a study from another
group) is contradictory with its melanogenic effect reported in a model of melanophores from wall
lizard [30]. Several factors may account for this contradiction. First, BCSE’s effects on melanogenesis
were assessed with different models (murine melanoma cells vs. wall lizard melanophores), which may
have distinct response to the treatment with BCSE. Next, levels of TQ in BCSE used in the wall lizard
melanophores study and in Thymocid® are different (0.0356% vs. 5.12%). Therefore, further studies
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with more physiological relevant models including human melanocytes are warranted to confirm
the modulatory effects of Thymocid® on melanogenesis. Mechanistically, our studies showed that
Thymocid® inhibited cellular tyrosinase activity (Figure 4D) and suppressed the gene and protein
expressions of melanogenesis-related markers in B16F10 cells (Figures 5 and 6), which may collectively
contribute to its overall antimelanogenic effects. We noted that Thymocid® was able to downregulate
both gene and protein expression of TYRP1 in B16F10 cells. TYRP1 is an enzyme catalyzing the
oxidation of dihydroxyindole carboxylic acid during the process of melanin biosynthesis in murine
melanoma cells [47]. In addition, TYRP1 is involved in maintaining the protein structure of tyrosinase
and modulating its oxidative activity, which was in agreement with the observation of decreased
cellular tyrosinase activity in B16F10 cells. Therefore, TYRP1 may be a valid molecular target for the
antimelanogenic effects of Thymocid® . However, further studies with human melanocytes as well as
in skin tissue architecture that simulate human skin are warranted to confirm this. In addition, further
studies on Thymocid® ’s cosmeceutical characterizations including skin permeability, bioavailability,
and proper formulations are warranted.
5. Conclusions
In summary, Thymocid® , a chemically standardized and commercially available BCSE, protected
the structure of BSA and type I collagen by inhibition of protein glycation and collagen cross-linking,
respectively. Thymocid® also inhibited the activity of skin-wrinkle-related enzymes including
collagenase and elastase. The inhibitory effects of Thymocid® on collagenase and elastase may
contribute to its overall anti-aging effects. In addition, Thymocid® showed inhibitory effects on the
production of melanin content in B16F10 cells. This antimelanogenic effect was associated with its
modulation of cellular tyrosinase activity and expressions of melanogenesis-related genes and proteins
including MITF, TYR, TYRP1, and TYRP2. Our findings highlight the potential of Thymocid® as a
bioactive ingredient for cosmeceutical applications.
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Abbreviations
AG
AGEs
AAAPVN
BCSEs
BSA
EGCG
FALGPA
L-DOPA
MGO
MITF
phen
TQ
TYR
TYRP1
TYRP2

aminoguanidine
advanced glycation end-products
N-succinyl-Ala-Ala-Ala-p-nitroanilide
black cumin seed extracts
bovine serum albumin
epigallocatechin gallate
N-(3-[2-furyl]-acryloyl)-Leu-Gly-Pro-Ala
L-3,4-dihydroxyphenylalanine
methylglyoxal
microphthalmia-associated transcription factor
1,10-phenanthroine
thymoquinone
tyrosinase
tyrosinase-related protein-1
tyrosinase-related protein-2
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